Loading
MT
Mersana Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 02 Jun 2022.
Mersana Therapeutics, Inc.: what insiders have been doing
This page follows insider dealings at Mersana Therapeutics, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Between 18 October 2025 and 18 October 2026, 13 insiders published 16 filings.
All open-market trades in the period are sales: 1 sale worth €655, by 1 insider, with no purchase on record. At €655, the sale published on 28 October 2025 by Bala Mohan is the largest of the period.
A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Compared with its exchange (5,816 companies, median 19 filings), a count of 16 filings is below the norm. Our records for Mersana Therapeutics, Inc. go back to 2021, with 10 purchases and 3 sales on the open market in total.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
107
Thresholds
n/a
Buy Volume
€19M
10 ops. · all time
Sell Volume
€14,785
3 ops. · all time
Who traded when
BuySaleMohan Bala1 sale
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
Income statement
RevenueUS$34.9M
Net income-US$59.6M-170.9% margin
Last declaration on 6 January 2026
Declarations107 total
578 sharesCommon StockSEC:0001104659-26-001377:0
84 sharesCommon StockSEC:0001104659-26-001377:1
2,300 sharesCommon StockSEC:0001104659-26-001375:0
6,721 sharesCommon StockSEC:0001104659-26-001374:0
10,466 sharesCommon StockSEC:0001104659-26-001371:0
23,546 sharesCommon StockSEC:0001104659-26-001368:0
5,015 sharesCommon StockSEC:0001104659-26-001365:0
578 sharesCommon StockSEC:0001193125-26-004925:0
578 sharesCommon StockSEC:0001104659-26-001389:0
578 sharesCommon StockSEC:0001104659-26-001385:0
1,567 sharesCommon StockSEC:0001104659-26-001382:0
3,131 sharesCommon StockSEC:0001104659-26-001380:0
2,927 sharesCommon StockSEC:0001104659-26-001379:0
9,573 sharesCommon StockSEC:0001104659-26-001376:0
77 shares@ US$9.9016.5% of flowCommon StockSEC:0001104659-25-103170:1
250 shares0Common StockSEC:0001104659-25-103170:0
6,670 shares0Common StockSEC:0001104659-25-090026:0
12,500 shares0Common StockSEC:0001104659-25-004591:0
14,583 shares0Common StockSEC:0001104659-25-004590:0
7,291 shares0Common StockSEC:0001104659-25-004595:0
21,250 shares0Common StockSEC:0001104659-25-004596:0
11,062 shares0Common StockSEC:0001104659-25-004593:0
6,250 shares0Common StockSEC:0001104659-25-004592:0
4,519 shares0Common StockSEC:0001104659-25-004597:0
2,500 shares0Common StockSEC:0001104659-25-004180:0
25 of 107 declarations
About Mersana Therapeutics, Inc.
Mersana Therapeutics, Inc. (ticker: MRSN) is a U.S.-based biopharmaceutical company listed on the NASDAQ in the United States. For French-speaking investors, it is best viewed as a clinical-stage biotech story with the usual hallmarks of the sector: high R&D intensity, binary clinical-readout risk, potential dilution, and a business model still far from recurring commercial profitability. The company is headquartered in Cambridge, Massachusetts, and was founded in 2001. Its core strategy is centered on antibody-drug conjugates (ADCs), a class of targeted oncology therapies designed to deliver cytotoxic payloads more selectively to cancer cells than traditional chemotherapy. Mersana’s positioning is therefore that of a specialist in high unmet-need cancers, leveraging proprietary platforms rather than broad commercial infrastructure.([stockanalysis.com](https://stockanalysis.com/stocks/mrsn/company/?utm_source=openai))
From a business perspective, Mersana has evolved from an earlier-stage research company into a focused clinical biotech with a small number of lead assets. Its most visible programs are Emi-Le (emiltatug ledadotin, XMT-1660), a B7-H4-targeted Dolasynthen ADC, and XMT-2056, a HER2-targeted Immunosynthen ADC. The company’s differentiation lies in its technology stack, including the Dolasynthen and Immunosynthen platforms, which are intended to support the design of more selective and potentially better-tolerated ADCs. In other words, Mersana does not yet derive value from marketed products; its investment case depends on successful clinical development, regulatory progress, and the ability to translate platform science into attractive oncology candidates.([ir.mersana.com](https://ir.mersana.com/news-releases/news-release-details/mersana-therapeutics-announces-positive-initial-clinical-data?utm_source=openai))
Read moreShow less
Competitively, Mersana operates in one of the most crowded and strategically important areas of oncology. ADCs have attracted substantial interest from large pharmaceutical groups and specialist biotech peers alike, so Mersana’s edge is not scale, but rather target selection and platform differentiation. That said, the company has made tangible progress: it has reported clinical updates on both XMT-1660 and XMT-2056, and it has also disclosed collaboration activity with GSK around XMT-2056, including a $15 million development milestone in July 2025. These data points matter because they provide external validation for the platform, while also reinforcing the company’s dependence on partnership economics and pipeline execution.([ir.mersana.com](https://ir.mersana.com/news-releases/news-release-details/mersana-therapeutics-provides-business-update-and-announces-12?utm_source=openai))
Recent headlines also highlight the financing and listing-risk dimension of the story. In September 2025, Mersana disclosed that it had received a Nasdaq notice of non-compliance related to the minimum market value of listed securities requirement, while stating that its common stock continued to trade on the Nasdaq Global Select Market under the symbol MRSN. The company has also continued to raise capital and to update investors on clinical progress, which suggests a capital-intensive development path and a need to preserve optionality. For investors in Europe, MRSN remains a high-risk, high-volatility oncology name: the upside is tied to the scientific and clinical success of its ADC pipeline, but the near-term narrative is equally shaped by financing needs, Nasdaq compliance considerations, and the timing of future data releases.([ir.mersana.com](https://ir.mersana.com/static-files/501562f1-57b8-4b11-8522-c194a5cc58f6?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
